Technology | June 10, 2015

Cordis Corporation Expands Cordis Crossing Portfolio With New Support, Re-entry Catheters

New devices indicated for treatment of chronic total occlusions

Cordis Corp., Cordis Crossing Portfolio, Elitecross, Outback Elite, CTO

June 10, 2015 - Cordis Corp. announced the launch of the new Elitecross support catheter in the United States and Outback Elite re-entry catheter in the United States, Europe and Japan. This expands the Cordis Crossing Portfolio for treatment of chronic total occlusions (CTO), a suite of specialty and workhorse solutions designed to support physicians in crossing the most complex lesions.

A CTO occurs when the accumulation of plaque becomes so severe that it results in a complete or nearly complete blockage of the vessel. When this occurs, physicians must find a way to cross the occlusion in order to complete treatment of the lesion using interventional techniques.

"New and dedicated CTO crossing wires, re-entry devices and crossing catheters, combined with advancing technique have led to a significant improvement in success rates of CTO treatment in recent years," said Jihad Mustapha, M.D., FACC, FSCAI, director of heart and vascular at Metro Health Hospital in Wyoming, Michigan. "The expanded Cordis Crossing portfolio enables physicians to further improve treatment success, and deliver the best possible care to the patients that rely on us every day."

The Cordis Crossing Portfolio reduces the complexity of challenging cases and provides a comprehensive crossing solution of specialty and workhorse devices. The new Elitecross support catheter features a braided shaft, tapered tip, lubricious hydrophilic coating and ultra low-friction inner lumen to enhance trackability over the guidewire. The device is designed to provide additional support to the distal portion of diagnostic or interventional devices, and is compatible with the Frontrunner XP CTO catheter as well as other ancillary devices.

The redesigned Outback Elite re-entry catheter enables faster and more precise re-entry into the true lumen in the most challenging cases, and represents the first ever re-entry device available in Japan. The device was redesigned with an ergonomic handle and torque control location, enabling single-handed operation by the user. The addition of an 80 cm shaft length will aid in optimizing procedures by reducing the length of shaft outside the patient. These new features combined with a redesigned package make the Outback Elite a more convenient, precision re-entry tool for the toughest lesions of peripheral vascular disease. In a recent study by Gandini et al., the Outback re-entry catheter was shown to have a higher success rate of precision re-entry versus manual wire techniques.

Cordis expects to launch the Elitecross in Europe and Japan in the coming months.

For more information:

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Overlay Init